Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 268

Results For "LTI"

2943 News Found

U.S. FDA approves first treatment for drug-resistant post-transplant infection
Drug Approval | November 24, 2021

U.S. FDA approves first treatment for drug-resistant post-transplant infection

The approval is for Cytomegalovirus, a type of Herpes virus


Vivera announces launch of new testing software, LabPort
Digitisation | November 24, 2021

Vivera announces launch of new testing software, LabPort

Featuring identity verification using artificial intelligence (AI), LabPort was designed to facilitate immediate results reporting for diagnostic testing even in high-volume, field-based testing environments


Vital Strategies India appoints L. M. Singh as MD, India and Global Head, Partnerships and Innovative Finance
People | November 24, 2021

Vital Strategies India appoints L. M. Singh as MD, India and Global Head, Partnerships and Innovative Finance

In his new role as Managing Director India and Global Head, Partnerships and Innovative Finance, Singh will oversee the financial, human, and operational functions of the India office


Molbio has pioneered point of care molecular testing: Sriram Natarajan
interviews | November 22, 2021

Molbio has pioneered point of care molecular testing: Sriram Natarajan

Molbio Diagnostics has been the pioneer in providing access to molecular testing through its Truenat Real Time PCR platform. Sriram Natarajan, Director & CEO, of the company shares his experiences on the journey so far in an interview with Thomas C Thottathil


HCG acquires Suchirayu Healthcare Solutions
Hospitals | November 22, 2021

HCG acquires Suchirayu Healthcare Solutions

Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds


CStone and Jiangsu Hengrui sign exclusive licensing agreement for cancer drugs in China
Biotech | November 22, 2021

CStone and Jiangsu Hengrui sign exclusive licensing agreement for cancer drugs in China

CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region


Merck showcases potential for several cancers, MS and lupus
News | November 22, 2021

Merck showcases potential for several cancers, MS and lupus

Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline


Laurus Labs acquires stake in IIT Bombay incubated ImmunoACT
News | November 20, 2021

Laurus Labs acquires stake in IIT Bombay incubated ImmunoACT

ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.


Funding push to pharma R&D critical for unleashing next phase of growth
News | November 20, 2021

Funding push to pharma R&D critical for unleashing next phase of growth

The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation


Novo Nordisk to acquire Dicerna Pharmaceuticals for US $ 3.3 bn
Biotech | November 20, 2021

Novo Nordisk to acquire Dicerna Pharmaceuticals for US $ 3.3 bn

Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease